Zomedica Corp. - ZOM STOCK NEWS

Zomedica Corp. (NYSE American:ZOM) is set to be featured on The RedChip Money Report airing on Bloomberg TV on April 1, 2023, at 7 p.m. ET. This interview aims to provide insights into Zomedica's operations in the veterinary health sector, focusing on products for clinical veterinarians and enhancing animal care. The show, with an estimated reach of 73 million homes in the U.S., is part of RedChip Companies' effort to highlight microcap and small-cap stocks.
For complete access to the interview, visit here.

Zomedica Corp. (NYSE American:ZOM) announced the appointment of Peter L. Donato as its new Chief Financial Officer, effective March 16, 2023. With over 30 years of experience primarily in the human health sector, Donato's background includes significant roles such as CFO and CEO. He previously led a consulting practice focusing on public company readiness and served as CFO at Standard Bariatrics. Donato succeeds Ann Marie Cotter, who is retiring after contributing significantly to the company. Zomedica emphasizes that Donato's diverse expertise will support the company's growth and enhance care for companion animals.

Zomedica Corp. (NYSE American:ZOM) reported significant growth in its 2022 financial results, with revenue surging to $18.9 million, a 361% increase from 2021. This growth is attributed to the full-year impact of the PulseVet platform and the recently acquired Assisi products, contributing combined revenues of $18.5 million.

Gross margin stood at 72%, with a net loss of $17.0 million, slightly improved from the previous year. Zomedica ended 2022 with $156 million in liquidity and plans to expand its product offerings with new launches in 2023.

Zomedica Corp. (NYSE American:ZOM) will host a conference call on March 15, 2023, at 4:30 p.m. ET to discuss operational and financial highlights for the fourth quarter and fiscal year ended December 31, 2022. Interested parties can join the live call at +1-877-407-0789 (U.S. Toll-Free) or via webcast. A replay of the call will be available until March 29, 2023. Zomedica focuses on creating innovative diagnostic and therapeutic products for companion animals, aiming to enhance veterinary practices.

Zomedica Corp. (NYSE American: ZOM) reported preliminary unaudited results for Q4 and the full year 2022. Q4 revenue is expected to be approximately $6.0-$6.2 million, marking an increase of 46-51% year-over-year, driven by PulseVet sales and the addition of Assisi products. For the full year, revenue is projected at $18.6-$18.9 million, reflecting a 354-361% increase from the previous year. The company anticipates a gross margin of about 72% for 2022. As of December 31, 2022, Zomedica expects to have approximately $156 million in cash and equivalents. The company plans to launch new products in 2023, including the VetGuardian monitor and the TRUVIEW microscopy platform.

Zomedica Corp. (NYSE American:ZOM) will be featured in an interview on The RedChip Money Report airing on Bloomberg TV on February 11, 2023, at 7 p.m. ET. The interview, which aims to enhance awareness of Zomedica's veterinary health initiatives, showcases insights from CEO Larry Heaton on improving pet care and creating new opportunities for veterinarians. The program is accessible to approximately 73 million households in the U.S. Zomedica is committed to addressing unmet needs in veterinary services with innovative diagnostic and medical products designed to boost veterinarian productivity and animal health.

Zomedica Corp. (NYSE American: ZOM) announced its participation in the Lytham Partners Investor Select Conference scheduled for January 31, 2023. The company's webcast presentation will be accessible from 9:00 AM ET on that date through a provided link, and will later be available on their official website. In addition to the webcast, Zomedica's management will hold virtual one-on-one meetings during the event. Stakeholders can arrange these meetings by contacting Lytham Partners directly. Zomedica is focused on veterinary health, developing innovative diagnostics and medical devices for companion animals.

Zomedica Corp. (NYSE American: ZOM) announced a strategic restructuring of its partnership with Qorvo Biotechnologies to take control over the development and manufacturing of its TRUFORMA product line. This change is projected to accelerate the rollout of new diagnostic assays while reducing costs. The restructuring allows Zomedica to eliminate new customer acquisition expenses as it expands its installed base of TRUFORMA instruments. The agreements include licensing payments and technology transfer assistance, enabling Zomedica to directly manage the manufacturing process within 18 months. Zomedica aims to enhance veterinary diagnostics with its innovative technology.

Zomedica Corp. (NYSE American: ZOM) has partnered with Structured Monitoring Products, Inc. to launch the VetGuardian zero-touch vital signs remote monitoring system for veterinary professionals. This innovative system allows for contact-free, continuous monitoring of pets' vital signs, including temperature, pulse, and respiration, enhancing patient care while minimizing stress. It features patented technology that enables real-time data capture without the need for harnesses. Zomedica aims to market VetGuardian to veterinarians, diversifying their product range and addressing staffing challenges in veterinary clinics, especially in post-surgical and ICU monitoring.